Acute Lymphoblastic Leukemia PDX Models

Most commercially available blood cancer Patient Derived Xenograft (PDX) models are transient in nature, and non-transferable through passages (not renewable), without disease symptoms or mortality. However, CrownBio’s PDX models for blood cancer are permanent, and allow the study of disease recurrence after initial treatment challenge and the efficacy testing of novel agents against drug resistance. The CrownBio ALL PDX collection consists of a wide range of models, including models with patient-relevant mutations e.g. BCR/ABL(+). More

Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL ID CANCER TYPE SUBTYPE models per page
AL5503 Acute Lymphoblastic Leukemia B VIEW MODEL Details
AL5511 Acute Lymphoblastic Leukemia T VIEW MODEL Details
AL5514 Acute Lymphoblastic Leukemia B VIEW MODEL Details
AL5518 Acute Lymphoblastic Leukemia B VIEW MODEL Details
AL5521 Acute Lymphoblastic Leukemia B VIEW MODEL Details
AL7015 Acute Lymphoblastic Leukemia B VIEW MODEL Details
AL7119 Acute Lymphoblastic Leukemia B VIEW MODEL Details
AL7142 Acute Lymphoblastic Leukemia T VIEW MODEL Details
AL7155 Acute Lymphoblastic Leukemia B VIEW MODEL Details
AL7174 Acute Lymphoblastic Leukemia T VIEW MODEL Details